CRC Research Update — September 05, 2026
Today's colorectal cancer research highlights
ctdna
A collection of 87 issues
Immune Recovery After Surgery Linked to ctDNA Minimal Residual Disease
Skip to content
The CRC Digest
Immune Recovery After Surgery Linked to ctDNA Minimal Residual Disease
A prospective study of 1,000 stage II-III CRC patients found that distinct perioperative immunocircadian recovery trajectories were associated with postoperative ctDNA-based minimal residual disease and long-term survival outcomes. (Surgery)
This content is informational
Circulating Tumor DNA Predicts Recurrence After Liver Metastasis Resection
Skip to content
The CRC Digest
◇ RESEARCH
Circulating Tumor DNA Predicts Recurrence After Liver Metastasis Resection
A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) serves as a biomarker for recurrence after curative resection of colorectal cancer liver metastases, potentially guiding post-surgical surveillance strategies. (Clinical Colorectal Cancer)
This
CRC Research Update — September 02, 2026
Today's colorectal cancer research highlights
Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRC
Skip to content
The CRC Digest
◇ RESEARCH
Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRC
Research published in JCO Precision Oncology explores how relative mutant allele frequency in circulating tumor DNA (ctDNA) could help determine when to rechallenge patients with anti-EGFR therapy after resistance develops.
CRC Research Update — September 01, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 31, 2026
Today's colorectal cancer research highlights
Phase III trial shows circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase III trial shows circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer
The prospective, randomized FIND trial used dynamic ctDNA methylation monitoring to personalize follow-up care after surgery in stage I-III patients. (Journal of Clinical Oncology)
This
CRC Research Update — August 30, 2026
Today's colorectal cancer research highlights
Whole-Genome Electrical Impedance Assay Detects DNA Hypomethylation for CRC Screening
Skip to content
The CRC Digest
▪ SCREENING
Whole-Genome Electrical Impedance Assay Detects DNA Hypomethylation for CRC Screening
A rapid, label-free cell-free DNA assay measures global DNA hypomethylation—a hallmark of colorectal cancer—using electrical impedance to differentiate healthy individuals from those with cancer in a retrospective validation study. (Computational and